Description
DK
Dr. Daria KwaśniewskaESMO Certified Consultant Medical Oncologist
Reviewed June 2026
⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. Dosing is highly indication- and weight-specific; only your oncologist can determine the correct dose for you.
Is Lenvanix right for your situation?
Review these criteria with your oncologist before enquiring✔ You may be a candidate if
- ✓Radioactive iodine-refractory differentiated thyroid cancer (DTC)
- ✓Advanced renal cell carcinoma (RCC), in combination with pembrolizumab or everolimus
- ✓Unresectable hepatocellular carcinoma (HCC), first-line
- ✓Advanced endometrial carcinoma, in combination with pembrolizumab
✖ May NOT be suitable if
- ✗Uncontrolled hypertension
- ✗Recent or active severe bleeding
- ✗Pregnant, planning pregnancy, or breastfeeding
- ✗Surgery planned within the next 4 weeks
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Lenvanix?
Lenvanix is a generic formulation of Lenvatinib — a multi-target tyrosine kinase inhibitor (TKI) — manufactured by Beacon Pharmaceuticals Ltd., Bangladesh’s largest dedicated oncology pharmaceutical company, under WHO-GMP certified conditions. Lenvanix contains the same active molecule found in Lenvima® (Eisai/Merck) and is dispensed under the Named Patient Program.
Lenvanix is a generic small-molecule drug, not a chemotherapy agent. It works by blocking specific growth and blood-vessel signalling pathways rather than broadly damaging dividing cells.
| Generic name | Lenvatinib (mesylate) |
| Reference brand | Lenvima® (Eisai / Merck) |
| Manufacturer | Beacon Pharmaceuticals Ltd. |
| Standard | WHO-GMP Certified |
| Drug class | Multi-target Tyrosine Kinase Inhibitor |
| Dosage form | Capsule — multiple strengths |
| Route | Oral · once daily, with or without food |
| Prescription | Required — oncologist only |
How Lenvatinib Works
Lenvatinib inhibits multiple tyrosine kinases involved in tumour growth and blood vessel formation: VEGFR-1, -2, and -3, FGFR1-4, PDGFR-alpha, RET, and KIT.
By blocking VEGFR signalling, lenvatinib has strong anti-angiogenic effects — cutting off the new blood vessel growth that tumours need to expand and metastasise. Blocking the additional kinases (FGFR, RET, KIT, PDGFR-alpha) adds direct anti-proliferative effects against the cancer cells themselves. This dual mechanism is why lenvatinib is active across several genetically distinct cancer types — thyroid, kidney, liver, and endometrial cancers all depend on overlapping elements of this signalling network.
Dosing by Indication
Dosing is indication-specific and, for liver cancer, weight-based — never assume one indication’s dose applies to another.
| Thyroid cancer (DTC) | 24 mg once daily (monotherapy) |
| Kidney cancer (RCC), first-line | 20 mg once daily + pembrolizumab |
| Kidney cancer (RCC), with everolimus | 18 mg once daily + everolimus 5 mg |
| Liver cancer (HCC), ≥60 kg body weight | 12 mg once daily |
| Liver cancer (HCC), <60 kg body weight | 8 mg once daily |
| Endometrial cancer | 20 mg once daily + pembrolizumab |
Side Effects
Common
- Hypertension (very common)
- Fatigue
- Diarrhoea, nausea, stomatitis
- Decreased appetite
- Hand-foot skin reaction
- Proteinuria
- Dysphonia (voice changes)
Serious · Report Immediately
- Severe hypertension / hypertensive crisis
- Cardiac dysfunction, arrhythmia
- Serious haemorrhage
- Arterial thromboembolic events (stroke, heart attack)
- Hepatotoxicity, GI perforation (rare)
⚠ Seek emergency care immediately for:
- Severe headache, very high blood pressure reading, or vision changes
- Unusual bleeding that won’t stop, or blood in vomit/stool
- Sudden weakness, confusion, or difficulty speaking
How to Take Lenvanix
- 1Once daily, same time each day — with or without food.
- 2Swallow capsules whole with water. Do not crush or chew.
- 3Do not combine with alcohol.
- 4If unable to swallow capsules, an oral suspension method exists but must follow the exact procedure your oncologist or pharmacist specifies — do not attempt to dissolve capsules yourself without direct medical guidance on the precise method and timing.
- 5Storage: room temperature, dry place, out of reach of children.
Frequently Asked Questions
Is lenvatinib a chemotherapy drug?
No. Lenvatinib is a targeted therapy — a tyrosine kinase inhibitor — that blocks specific molecules driving tumour growth and blood vessel formation, rather than broadly damaging all rapidly dividing cells the way traditional chemotherapy does.
What is the difference between Lenvanix and Lenvaxen?
Both contain the same active ingredient, lenvatinib, at WHO-GMP certified quality. The distinction is manufacturer: Lenvanix is made by Beacon Pharmaceuticals, Lenvaxen by Everest Pharmaceuticals. Contact us to confirm current availability for your country.
Can lenvatinib be combined with pembrolizumab and everolimus?
Yes — lenvatinib is approved in combination with both pembrolizumab (for RCC and endometrial cancer) and everolimus (for RCC, second-line). Each combination has its own specific lenvatinib dose. Your oncologist determines the correct combination and dose based on your diagnosis and treatment line.
Is dose reduction during treatment normal?
Yes. The majority of patients require at least one dose reduction due to side effects like hypertension. This follows a standard, structured protocol and does not mean the medicine has stopped working.
How do I order Lenvanix through Meds For Cancer?
Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist’s prescription specifying your diagnosis, weight (if HCC), and exact strength/quantity required. Our team will verify the prescription and arrange secure international shipping under the Named Patient Program.
🛡 Named Patient Program
Meds For Cancer operates as a Named Patient Program (NPP) facilitator. WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription.
Clinical References
- Schlumberger M, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer (SELECT). NEJM 2015;372:621–630.
- Motzer RJ, et al. Lenvatinib plus pembrolizumab or everolimus for advanced RCC. NEJM 2021;384:1289–1300.
- Kudo M, et al. Lenvatinib versus sorafenib in HCC (REFLECT). Lancet 2018;391:1163–1173.
- FDA Prescribing Information: Lenvima (lenvatinib). Eisai, 2023.
Reviews
There are no reviews yet.